Evidence map›Paper›PMID 33977375›Full record

ArticleSurgical endoscopy2022

Three-months duration of fully-covered metal stent for refractory dominant extra-hepatic biliary stricture among primary sclerosing cholangitis patients: efficacy and safety.

Wisam Sbeit, Tawfik Khoury, Eran Goldin, Mahmud Mahamid

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Endoscopic management of primary sclerosing cholangitis.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025
    Review
  3. [Primary sclerosing cholangitis-Diagnosis and treatment 2024].Innere Medizin (Heidelberg, Germany) · 2024
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Wisam Sbeit *Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel.
Tawfik Khoury *Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel. tawfikkhoury1@hotmail.com.
Eran GoldinDepartment of Gastroenterology and Liver Diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Mahmud MahamidDepartment of Gastroenterology and Liver Diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Bar-Ilan University · ILHebrew University of Jerusalem · ILShaare Zedek Medical Center · ILWestern Galilee Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDominant stricture (DS) is a main cause of complication among patients with Primary Sclerosing Cholangitis (PSC). Endoscopic treatment options include dilation and plastic stenting, each with its own benefits and drawbacks.

aimsThe aim of the current study is to assess the safety and efficacy of fully-covered metal stent (FCMS) in these patients.

methodsA retrospective study of PSC patients with refractory DS, defined as strictures resistance to conventional therapy (balloon dilatation, plastic biliary stent insertion or both) and who underwent FCMS insertion for 3 months were included. The primary outcome was defined as clinical and laboratory improvement, while secondary outcomes were DS resolution upon stent removal and cholangiographic DS recurrence at 12-months after FCMS extraction.

resultsTwenty patients were enrolled from January 2016 through January 2020. Improvement in weakness and pruritus were seen in 80% and 35%, 75% and 65%, 75% and 35% of patients at 1-3 and 6 months following FCMS removal, respectively. Similarly, consistent improvement in all liver enzymes and total bilirubin were seen in up to 6 month following stent removal. Only one patient (5%) needed premature FCMS removal due to cholangitis 1 week after stent placement and 2 cases (10%) of stent related pancreatitis were encountered. At 3-months all remaining stents were softly removed. Cholangiographic DS resolution was demonstrated in 13 patients (65%) after stent removal at 3-months, and DS recurred in 4 patients (4/13 = 30.7%) at 12-months following stent removal. Notably, only proximal biliary DS location showed a trend for DS recurrence (OR 28.6, P = 0.06).

conclusionTemporary 3 months duration FCMS was feasible, safe and effective treatment option among patients with PSC related refractory DS.

Indexed as

Cholangitis, SclerosingCholestasisCholangiopancreatography, Endoscopic RetrogradeConstriction, PathologicHumansLiverMetalsNeoplasm Recurrence, LocalPlasticsRetrospective StudiesStentsTreatment OutcomeMetalsPlasticsDominantMetallicPSCStentStricture

Identifiers

PMID33977375
OpenAlexW3160154466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.